Dicerna Pharmaceuticals (DRNA) Jumps 6.67% on January 14

Equities Staff |

Dicerna Pharmaceuticals (DRNA) was among the biggest gainers on the Russell 2000 for Thursday January 14 as the stock popped 6.67% to $7.68, representing a gain of $0.48 per share. Some 58,101 shares traded hands on 644 trades, compared with an average daily volume of 146,203 shares out of a total float of 20.59 million. The stock opened at $7.20 and traded with an intraday range of $7.79 to $6.59.

After today's gains, Dicerna Pharmaceuticals reached a market cap of $158.16 million. Dicerna Pharmaceuticals has had a trading range between $27.33 and $7.19 over the last year, and it had a 50-day SMA of $11.85 and a 200-day SMA of $13.63.

Dicerna Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Dicerna Pharmaceuticals is based out of Cambridge, MA and has some 42 employees. Its CEO is Douglas M. Fambrough.

For a complete fundamental analysis analysis of Dicerna Pharmaceuticals, check out Equities.com’s Stock Valuation Analysis report for DRNA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets

Dropbox, Inc.

Dropbox is a service that allows their users to bring all photos, docs, and videos anywhere, and share them easily. Any file saved to Dropbox will automatically save to all…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…